Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Manish Patel, Paul Hamlin, MD, Donald K Strickland, MD, Anjali Pandey, PhD, Greg Coffey, PhD, Janet M Leeds, PhD, Gallia G. Levy, MD PhD, John T. Curnutte, MDPhD, Nina Wagner-Johnston, Ian W. Flinn, MD

Blood (2014) 124 (21): 3103.

https://doi.org/10.1182/blood.V124.21.3103.3103

Published: 2014

Journal Articles

Safety and Early Efficacy in an Ongoing Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 30 Gray Involved-Site Radiotherapy for Newly Diagnosed, Early Stage, Unfavorable Risk Hodgkin Lymphoma

Blood (2014) 124 (21): 3085.

https://doi.org/10.1182/blood.V124.21.3085.3085

Published: 2014

Journal Articles

Identification of Actionable Genomic Alterations Across Different Lymphoma Histologies Using a Comprehensive Next Generation Genomic Sequencing Clinical Assay

Blood (2014) 124 (21): 3000.

https://doi.org/10.1182/blood.V124.21.3000.3000

Published: 2014

Journal Articles

Safety and Early Efficacy Analysis of a Novel Combination of the PARP Inhibitor Veliparib (ABT-888) Plus Bendamustine and Rituximab in Patients with Lymphoma

John F. Gerecitano, MD PhD, Paul Hamlin, MD, Steven M. Horwitz, MD, Matthew J Matasar, MD MS, Alison J. Moskowitz, MD, Craig H. Moskowitz, MD, Ariela Noy, MD, Carol S Portlock, MD, Maria Lia Palomba, MD, David J. Straus, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Alice Chen, MD, Richard F Little, MPH, MD, France Fallon, Juho Whang

Blood (2014) 124 (21): 1739.

https://doi.org/10.1182/blood.V124.21.1739.1739

Published: 2014

Journal Articles

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Craig H. Moskowitz, MD, Andres Forero-Torres, MD, Bijal D. Shah, MD, Ranjana Advani, MD, Paul Hamlin, MD, Stella Kim, MD, Ana Kostic, MD, Larissa Sandalic, MS, Baiteng Zhao, PhD, Michelle A. Fanale, MD

Blood (2014) 124 (21): 1741.

https://doi.org/10.1182/blood.V124.21.1741.1741

Published: 2014

Journal Articles

Ofatumumab-Bendamustine As First Line Treatment for Elderly Patients with Mantle Cell Lymphoma: A Phase II Risk Adapted Design with Comprehensive Geriatric Assessment

Carla Casulo, MD, Augustine Iannotta, BS, Jannelle Walkley, BS, Craig H. Moskowitz, MD, Alison J Moskowitz, MD, Pamela Drullinsky, MD, Andrew D. Zelenetz, MD PhD, Paul Hamlin, MD

Blood (2014) 124 (21): 1751.

https://doi.org/10.1182/blood.V124.21.1751.1751

Published: 2014

Journal Articles

Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects

Karuna Ganesh, MBBChir, PhD, Connie Batlevi, MD PhD, Zhigang Zhang, PhD, Hani Hassoun, MD, Nikoletta Lendvai, MD PhD, Heather Landau, MD, Craig H. Moskowitz, MD, Philip Caron, MD PhD, Robert Motzer, MD, Sergio A Giralt, MD, Paul Hamlin, MD, Stuart M. Lichtman, MD, Matthew J. Matasar, MD MS, Carol S Portlock, MD, Neerav Shukla, MD, Carol Wasserheit-Lieblich, MD, Andrew D. Zelenetz, MD PhD, John F. Gerecitano, MD PhD

Blood (2014) 124 (21): 3487.

https://doi.org/10.1182/blood.V124.21.3487.3487

Published: 2014

Journal Articles

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Mitul D. Gandhi, Andrew M. Evens, Timothy S. Fenske, Paul Hamlin, Bertrand Coiffier, Andreas Engert, Alison J. Moskowitz, Nilanjan Ghosh, Adam M. Petrich, Jon Lomasney, Amy Chadburn, Gary S. Wood, Katrin Salva, Beatrice Nardone, Steven M. Trifilio, Dennis W. Raisch, Dennis P. West, Leo I. Gordon, Jane N. Winter

Blood (2014) 123 (18): 2895–2897.

https://doi.org/10.1182/blood-2014-03-561878

Published: 2014

Journal Articles

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Mitul Gandhi, MD, Andrew M Evens, DO, MSc, Timothy S. Fenske, MD, Paul Hamlin, MD, Bertrand Coiffier, MD, PhD, Andreas Engert, MD, Alison J. Moskowitz, MD, Nilanjan Ghosh, MD, PhD, Adam M. Petrich, MD, Jon Lomasney, M.D., Amy Chadburn, M.D., Gary S. Wood, MD, Katrin Salva, M.D., Steven M Trifilio, BS Pharm, Dennis W. Raisch, PhD, MS, RPh, Dennis West, PhD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2013) 122 (21): 4380.

https://doi.org/10.1182/blood.V122.21.4380.4380

Published: 2013

Journal Articles

FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant For Relapsed and Refractory Hodgkin Lymphoma

Alison Moskowitz, MD, Heiko Schoder, MD, John F. Gerecitano, MD, PhD, Paul Hamlin, MD, Steven M. Horwitz, MD, Matthew J Matasar, MD, MS, Vahakn S Keskinyan, Susan McCall, Ariela Noy, MD, M. Lia Palomba, MD, Carol S. Portlock, MD, David J Straus, MD, Joachim Yahalom, MD, Anas Younes, MD, Andrew D Zelenetz, MD, PhD, Craig H. Moskowitz, MD

Blood (2013) 122 (21): 2099.

https://doi.org/10.1182/blood.V122.21.2099.2099

Published: 2013

Journal Articles

Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL)

Craig H. Moskowitz, MD, Heiko Schoder, Paul Hamlin, MD, Jocelyn C Maragulia, Janelle Walkley, Andrew D. Zelenetz, MD, PhD

Blood (2012) 120 (21): 792.

https://doi.org/10.1182/blood.V120.21.792.792

Published: 2012

Journal Articles

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Craig H. Moskowitz, Matt J. Matasar, Andrew D. Zelenetz, Stephen D. Nimer, John Gerecitano, Paul Hamlin, Steven Horwitz, Alison J. Moskowitz, Ariela Noy, Lia Palomba, Miguel-Angel Perales, Carol Portlock, David Straus, Jocelyn C. Maragulia, Heiko Schoder, Joachim Yahalom

Blood (2012) 119 (7): 1665–1670.

https://doi.org/10.1182/blood-2011-10-388058

Published: 2012

Journal Articles

Elderly Hodgkin Lymphoma At MSKCC From 1994–2008: Characteristics, Outcome and Risk Factor Analysis in 133 Patients,

Zachary H Word, MD, Jocelyn C Maragulia, Janelle Walkley, Daniel R. Smith, Paul Hamlin, MD

Blood (2011) 118 (21): 3648.

https://doi.org/10.1182/blood.V118.21.3648.3648

Published: 2011

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, MD, John Sweetenham, MD, Ying Jiang, PhD, Sharon T Sullivan, PhD, Erik R Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2011) 118 (21): 2718.

https://doi.org/10.1182/blood.V118.21.2718.2718

Published: 2011

Journal Articles

Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience

Matthew Alexander Lunning, DO, Erika Pamer, BA, Lauren Wintman, BS, Valkal Bhatt, PharmD, Joachim Yahalom, MD, Alison J. Moskowitz, MD, Jenna D Goldberg, MD, David J. Straus, MD, Paul Hamlin, MD, Andrew D Zelenetz, MD, PhD, Steven M. Horwitz, MD

Blood (2011) 118 (21): 2688.

https://doi.org/10.1182/blood.V118.21.2688.2688

Published: 2011

Journal Articles

Older Age and Co-Morbidities Do Not Predict Incidence of Dose Limiting Toxicities in Lymphoma Phase I Trials At MSKCC

Natraj R Ammakkanavar, MD, Chady Abboud Leon, MD, Paul Hamlin, MD

Blood (2011) 118 (21): 3145.

https://doi.org/10.1182/blood.V118.21.3145.3145

Published: 2011

Journal Articles

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Razelle Kurzrock, MD, Paul Hamlin, M.D., Anas Younes, M.D., David Hong, M.D., Michael Gordon, M.D., Matthew A. Spear, M.D., Michael A. Palladino, Ph.D., G. Kenneth Lloyd, Ph.D., Angie M. Longenecker, R.N., Saskia T.C. Neuteboom, Ph.D., Gillian F. Cropp, M.S., Alison Hannah, M.D., Carol Aghajanian, M.D.

Blood (2007) 110 (11): 4504.

https://doi.org/10.1182/blood.V110.11.4504.4504

Published: 2007

Journal Articles

Pattern of Single Agent Rituximab Usage in Indolent Lymphoma and CLL beyond GELF and NCI Criteria.

Cheryl Cohler, Yael Brick-Turin, BA, Paul Hamlin, MD, Carol Portlock, MD, Andrew D. Zelenetz, MD, PhD, Ariela Noy, MD

Blood (2007) 110 (11): 4508.

https://doi.org/10.1182/blood.V110.11.4508.4508

Published: 2007

Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD

Blood (2006) 108 (11): 2759.

https://doi.org/10.1182/blood.V108.11.2759.2759

Published: 2006

Journal Articles

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Steven Horwitz, MD, Craig Moskowitz, MD, Tarun Kewalramani, MD, Paul Hamlin, MD, David Straus, MD, Owen O’Connor, MD, PhD, Ariela Noy, MD, Carol Portlock, MD, Stephen Nimer, MD, PhD, M. Lia Palomba, MD, PhD, Andrew Zelenetz, MD, PhD

Blood (2005) 106 (11): 2679.

https://doi.org/10.1182/blood.V106.11.2679.2679

Published: 2005

NARROW

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Safety and Early Efficacy in an Ongoing Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 30 Gray Involved-Site Radiotherapy for Newly Diagnosed, Early Stage, Unfavorable Risk Hodgkin Lymphoma

Identification of Actionable Genomic Alterations Across Different Lymphoma Histologies Using a Comprehensive Next Generation Genomic Sequencing Clinical Assay

Safety and Early Efficacy Analysis of a Novel Combination of the PARP Inhibitor Veliparib (ABT-888) Plus Bendamustine and Rituximab in Patients with Lymphoma

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Ofatumumab-Bendamustine As First Line Treatment for Elderly Patients with Mantle Cell Lymphoma: A Phase II Risk Adapted Design with Comprehensive Geriatric Assessment

Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant For Relapsed and Refractory Hodgkin Lymphoma

Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL)

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Elderly Hodgkin Lymphoma At MSKCC From 1994–2008: Characteristics, Outcome and Risk Factor Analysis in 133 Patients,

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience

Older Age and Co-Morbidities Do Not Predict Incidence of Dose Limiting Toxicities in Lymphoma Phase I Trials At MSKCC

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Pattern of Single Agent Rituximab Usage in Indolent Lymphoma and CLL beyond GELF and NCI Criteria.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only